12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers CareCloud (NASDAQ:CCLDO) stock moved upwards by 46.1% to $15.5 during Tuesday’s pre-market session. Syra Health (NASDAQ:SYRA) shares…
Acumen Pharmaceuticals Says First Patient Dosed In ALTITUDE-AD, A Phase 2 Clinical Trial Of Sabirnetug In Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease
Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany on track to initiate
Acumen Pharmaceuticals Secures $50.0M Credit Facility with K2 HealthVentures
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter.
• Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Acumen Pharmaceuticals’s Earnings Outlook
Acumen Pharmaceuticals (NASDAQ:ABOS) is set to give its latest quarterly earnings report on Monday, 2023-11-13. Here’s what investors…
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen And Safety Findings For ACU193 In Early Alzheimer’s Disease At The 16th Annual Clinical Trials On Alzheimer’s Disease
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid
Acumen Pharmaceuticals To Present Deeper Insights From First-In-Human Phase 1 Study Of ACU193 For Early Alzheimer’s During Symposium At The 16th Annual Clinical Trials On Alzheimer’s Disease
Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included in a symposium on
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers icad (NASDAQ:ICAD) shares moved upwards by 69.7% to $3.5 during Tuesday’s regular session. The current volume of…